The TSC Preclinical Consortium invites nominations of compounds to test in one of four animal models relevant to TSC. The deadline for nominations is December 23.
Starting in January, the TSC Alert e-newsletter will be sent out on the second Friday of the month. Furthermore, the TSC Alliance is transitioning to a new email platform in 2020. If you do not receive the January TSC Alert or have any issues with the newsletter, please let us know: email@example.com.
The International Tuberous Sclerosis Complex Research Conference 2020: A Vision for the Future will take place November 12-14, 2020 at the Royal College of Physicians in London, UK. The conference will be organized by the Tuberous Sclerosis Association. Learn More
Hosted by The LAM Foundation, this conference attracts experts in every facet of clinical investigation and molecular and cellular biology, including clinical trialists, clinical investigators with expertise in interstitial lung disease and pleural disease, basic scientists from the pulmonary, TSC and smooth muscle communities, geneticists, and experts in lymphangiogenesis.
The TSC Alliance has partnered with Clinical Trial Connect to develop a user-friendly Clinical Trial Finder Tool to help individuals and families affected by TSC participate in relevant clinical trials. You can find the tool on our website here.
Information about the Warsaw Medical University study: Tuberous sclerosis complex (TSC) is a disease with a very high risk of epilepsy and its comorbidities, such as intellectual disability and autistic behavior with significant impact on the daily life of families with this condition.
Are you looking for samples from TSC patients to use in your lab? The TSC Biosample Repository has a growing collection of samples tied to phenotypic data. In most cases, we can ship these samples at no charge to the investigator.
The TuberOus SClerosis registry to increase disease Awareness (TOSCA) is an international disease registry designed to provide insights into the clinical characteristics of patients with Tuberous Sclerosis Complex (TSC). The aims of this study were to identify issues that arose during the design, execution, and publication phases of TOSCA, and to reflect on lessons learnt that may guide future registries in rare and complex diseases. Read the Article
The TSC Preclinical Consortium invites nominations of compounds to test in one of four animal models relevant to TSC. The deadline for nominations has been extended to December 23.
There are several opportunities to meet with TSC Alliance representatives during the 2019 American Epilepsy Society Annual Meeting: